Artiva Biotherapeutics, Inc. insider trading

Does following Artiva Biotherapeutics, Inc.’s insiders pay?

From May 13, 2026 to September 4, 2026, 12 insiders reported 10 open-market purchases and 9 sales not made under a pre-set plan in Artiva Biotherapeutics, Inc. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 14, 2026 into $3,923 by November 2, 2026, −86.4% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $10,162 (+3.5% a year), and held throughout $10,162 (+3.5%).

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.